- Conditions
- Psoriatic Arthritis
- Interventions
- Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 114
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Crohn's Disease
- Interventions
- Vedolizumab, Upadacitinib, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- La Jolla, California • Los Angeles, California • Colorado Springs, Colorado + 12 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 132
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
- Conditions
- EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
- Interventions
- Upadacitinib 30mg Dose, Upadacitinib Matching Placebo
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- Spondyloarthritis
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 41
- States / cities
- Flagstaff, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, Upadacitinib, Topical corticosteroids (TCS)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 1,533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Elsubrutinib, Upadacitinib, Placebo for elsubrutinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 78
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more
- Conditions
- Ankylosing Spondylitis (AS)
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Covina, California + 18 more
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Elsubrutinib, Placebo for elsubrutinib, Upadacitinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 47
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 40 more
- Conditions
- Psoriatic Arthritis, Spondyloarthritis, Axial
- Interventions
- Upadacitinib 15 MG [Rinvoq], Placebo
- Drug
- Lead sponsor
- CARE ARTHRITIS LTD.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Long COVID
- Interventions
- Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- Douglas D. Fraser
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California